EP1115409A4 - Composition for extending post meal satiety - Google Patents

Composition for extending post meal satiety

Info

Publication number
EP1115409A4
EP1115409A4 EP00950624A EP00950624A EP1115409A4 EP 1115409 A4 EP1115409 A4 EP 1115409A4 EP 00950624 A EP00950624 A EP 00950624A EP 00950624 A EP00950624 A EP 00950624A EP 1115409 A4 EP1115409 A4 EP 1115409A4
Authority
EP
European Patent Office
Prior art keywords
composition
weight
nutritional composition
meal
satiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00950624A
Other languages
German (de)
French (fr)
Other versions
EP1115409A1 (en
Inventor
Robert Portman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Consumer Care LC
Original Assignee
Kemin Consumer Care LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Consumer Care LC filed Critical Kemin Consumer Care LC
Publication of EP1115409A1 publication Critical patent/EP1115409A1/en
Publication of EP1115409A4 publication Critical patent/EP1115409A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a nutritional composition for extending satiety following a meal More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source of proteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety
  • a second approach has focused on slowing gastric emptying thereby creating a feeling of fullness
  • This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract
  • the disadvantage with the use of fiber is that the quantities needed to produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and dian iea
  • a third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP). Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut. Cholecystokinin has been shown to increase satiety.
  • CCK-RP When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal. Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.
  • a number of nutritive agents can stimulate the release of cholecystokinin.
  • proteins, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.
  • United States Patent No. 4,491 ,578 discloses the oral administration of a trypsin inhibitor to stimulate satiety by stimulating the release of cholecystokinin.
  • the trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.
  • the present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal
  • the dry nutritional composition includes proteins in the range of 10% to 80%
  • the protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine
  • the dry nutritional composition also includes the mineral calcium in the range of 2% to 6%
  • the calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc
  • the dry nutritional composition also includes medium and/or long chain fatty acids (C ⁇ 2 - C 22 ) in the range of 10%-40%
  • the dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%
  • Fig 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention
  • Fig 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention
  • the nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract of potatoes containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents
  • the proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21 ,000 It is both a trypsin and chymotrypsm inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin
  • the protease inhibitor with the desired activity is present m potatoes and m more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fibei Specifically, coarse potato flour available from Nonpa ⁇ el Company contains approximately 0 49 mg of potato protease inhibitor two per gram, and Paselh PPC potato flour av ailable fiom Avebe Company, The Netherlands, contains about 1 35
  • an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal
  • an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss
  • the source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention
  • coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water
  • teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components that may be added to the composition to improve characteristics such as mouth feel, taste, and the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nutritional composition in a dry powder form including an extract of potatoes that provides a source of proteinase inhibitor that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite. The nutritional composition includes between about 10 % and about 80 % by weight of a protein, between about 10 % and about 40 % by weight of a medium to long chain fatty acid, between about 2 % and about 5 % by weight of a calcium salt, and between about 1 % and about 5 % by weight of a proteinase inhibitor provided by the extract of potatoes.

Description

COMPOSITION FOR EXTENDING POST MEAL SATIETY
BACKGROUND OF THE INVENTION Field of Invention The present invention relates to a nutritional composition for extending satiety following a meal More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source of proteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety
Background of the Prior Art
Over the last forty years there has been extensive research conducted on mechanisms that would extend satiety following the ingestion of a meal The benefits of such an invention have obvious utility in producing weight loss Weight loss research has focused on three areas Because the brain plays an essential role in the control of appetite, researchers have looked at various neurotransmitters, specifically, serotonin, dopamine and nor-epinephrine A number of prescription and over-the-counter products have been developed which influence these neurotransmitters, thereby reducing appetite Reducing appetite pharmacologically has a number of drawbacks, including a loss of effectiveness over a period of time Drugs that affect neurotransmitters also affect the central nervous systems and can cause jitteriness and anxiety In addition, these agents can produce cardiovascular effects that may even be fatal
A second approach has focused on slowing gastric emptying thereby creating a feeling of fullness This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract The disadvantage with the use of fiber is that the quantities needed to produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and dian iea A third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP). Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut. Cholecystokinin has been shown to increase satiety. When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal. Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.
A number of nutritive agents can stimulate the release of cholecystokinin. Researchers have shown that protein, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.
United States Patent No. 4,491 ,578 discloses the oral administration of a trypsin inhibitor to stimulate satiety by stimulating the release of cholecystokinin. The trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.
A number of studies have shown that proteinase inhibitor extracted from potatoes stimulates the release of cholecystokinin. There is a definite need in the art for a nutritional intervention composition that can be taken orally, stimulate cholecystokinin levels prior to the initiation of a meal and sustain cholecystokinin levels and satiety for an extended period following consumption of a meal. An important element of this invention is the design of a product taken in a specified interval prior to the commencement of a meal. Thus, satiety levels are already enhanced before the meal, decreasing the quantity of food consumed during that meal.
SUMMARY OF THE INVENTION The present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal
The dry nutritional composition includes proteins in the range of 10% to 80% The protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine
The dry nutritional composition also includes the mineral calcium in the range of 2% to 6% The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc
The dry nutritional composition also includes medium and/or long chain fatty acids (Cι2- C22) in the range of 10%-40%
The dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%
BRIEF DESCRIPTION OF THE DRAWINGS Fig 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention
Fig 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract of potatoes containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents The proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21 ,000 It is both a trypsin and chymotrypsm inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin The protease inhibitor with the desired activity is present m potatoes and m more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fibei Specifically, coarse potato flour available from Nonpaπel Company contains approximately 0 49 mg of potato protease inhibitor two per gram, and Paselh PPC potato flour av ailable fiom Avebe Company, The Netherlands, contains about 1 35 mg potato protease inhibitor two per gram A method of extraction of a relatn el> puie proteinase inhibitor with the desired actn lty of the present invention is described m Bryant, J , Green, T R , Gurusaddalah, T , and Ryan, C A (\ 916), Bιochem 75, 3418 Experiment 1
This study was conducted with 21 subjects having a mean BMI =31 2 kg/m" (range 27 0 - 35 8) and mean age = 30 9 years (range 22 - 45) The study was a cross over design consisting of two parts In the fiist phase the subjects were either given a placebo whose lsocaloπc composition s equal to the nutritional drink composition or the nutritional dπnk composition Both treatments were administered m 8 oz of water 15 minutes prior to the meal The meal consisted of 460 calories Subjects were required to consume the meal within 15 minutes Following the consumption of the meal subjects were asked to rate their feelings of hunger and satiety on 6 \ lsual analog scales every 15 minutes for 3 !/_• hours The nutritional drmk composition is set out below
Nutritional Drink Composition
Constituent Grams %
Whey Protein 13 00 71 5
Non-Dairy Creamer 4 00 22 0 containing 50% oleic acid
Calcium Lactate 0 635 3 5
Flavor 0 19 1 0
Color 0 05 0 3
POT 21 0 30 1 7
POT 2 includes approx 1 % by weight of the proteinase inhibitor Hunger ratings following ingestion of the nutritional drink composition were significantly decreased throughout the post-meal measurement period, reaching a 30% decrease by 3 hours post meal (p=0 033) Consistent with this finding, fullness ratings were significantly greater starting 3 hours post meal (37% increase, p=0 043) No differences in subjective ratings of other hunger-related items, or in thirst, were observed between the conditions
Accordingly, an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal
Experiment 2
This study was conducted with 21 subjects having a mean BMI =31 2 kg/m2 (range 27 0 - 35 8) and mean age = 30 9 years (range 22 - 45) During the diet, subjects drank 8 oz (80 kcal) of the nutritional drink composition of Experiment 1 twice daily fifteen minutes before lunch and dinner The effect of the nutritional drink composition on satiety was measured in a laboratory before and in the fourth week of the diet On separate days subjects ingested the nutritional drink composition beverage or a placebo beverage (matched for volume and energy) fifteen minutes before a 350 calorie meal Subjects rated hunger and fullness on visual analog scales every 15 minutes for 3 Y2 hours The results of the study show that after four weeks on the diet, fullness ratings after lunch were higher after the consumption of the nutritional drink composition than the placebo beverage (mean ± SD for all time intervals = 71 0 ± 17 3 vs 65 5 ± 16 7, p < 0 05) Hunger ratings were 32% lower after the protease inhibitor than the placebo beverage (10 5 ± 12 0 vs 15 4 ± 13 3, p < 0 01) There were no adverse reactions to the nutritional drink composition, and subjects reported that it helped them to reduce their food intake Weight loss was significant (2 0 ± 1 1 kg in 4 weeks, p < 0 001 )
Accordingly an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss The source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention For example, while coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water Those having ordinary skill in the art, following the teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components that may be added to the composition to improve characteristics such as mouth feel, taste, and the like Although the description above contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of this invention

Claims

W 1 175 1
What is claimed is 1 A nutritional composition in a dry powder form that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite, comprising
(a) a protein comprising between about 10% and about 80% by weight of said dry composition,
(b) one or more fatty acids comprising between about 10% and about 40% by weight of said dry composition, (c) a calcium salt comprising between about 2% and about 5% by weight of said dry composition, and (d) an extract of potatoes pro iding a source of proteinase inhibitor that comprises between about 0 02% and about 5% by weight of said dry composition
2 A nutritional composition as defined in claim 1 , wherein said fatty acid comprises oleic acid
3 A nutritional composition as defined in claim 1 , further comprising a water soluble flavoring selected from the group including natural extracts and artificially produced extract components of apple, banana, cherry, cinnamon, cranberry, grape, honeydew, honey, kiwi, lemon, lime, orange, peach, peppeπnint, pineapple, raspberry, tangerine, watermelon, and wild cherry
4 A nutritional composition as defined in claiml , further comprising a colorant selected from the group including water soluble natural or artificial dyes of blue, green, orange, red, violet, and yellow
5 A nutritional composition as defined in claiml , further comprising a colorant selected from the group including iron oxide dyes, ultramarine pigments of blue, pink, red, and violet
EP00950624A 1999-07-27 2000-07-25 Composition for extending post meal satiety Withdrawn EP1115409A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14589299P 1999-07-27 1999-07-27
US145892P 1999-07-27
PCT/US2000/020157 WO2001017541A1 (en) 1999-07-27 2000-07-25 Composition for extending post meal satiety

Publications (2)

Publication Number Publication Date
EP1115409A1 EP1115409A1 (en) 2001-07-18
EP1115409A4 true EP1115409A4 (en) 2005-04-13

Family

ID=22515008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00950624A Withdrawn EP1115409A4 (en) 1999-07-27 2000-07-25 Composition for extending post meal satiety

Country Status (8)

Country Link
EP (1) EP1115409A4 (en)
JP (2) JP2003508490A (en)
KR (1) KR20010075394A (en)
AU (1) AU779377C (en)
BR (1) BR0006959A (en)
CA (1) CA2348067A1 (en)
MX (1) MXPA01003054A (en)
WO (1) WO2001017541A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334875A (en) * 2017-08-30 2017-11-10 南宁学院 A kind of medicinal liquor for treating diarrhoea and preparation method thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686456B2 (en) 2001-07-06 2004-02-03 Kemin Foods, L.C. Method for the elimination of Kunitz and Bowman-Birk trypsin inhibitors and carboxypeptidase inhibitor from potato proteins
JP2005015358A (en) * 2003-06-25 2005-01-20 Pharma Design Inc Medicinal composition used for treating eating disorder
US20090053199A1 (en) * 2005-04-11 2009-02-26 Zemel Michael B Stable Dairy Components Effective for Fat Loss
JP2010094085A (en) * 2008-10-17 2010-04-30 Pola Chem Ind Inc Food composition for dieting use
JP5691105B2 (en) * 2009-01-30 2015-04-01 株式会社東洋新薬 Taste improvement method of food containing potato extract
EP2227966B1 (en) * 2009-02-25 2016-07-27 Coöperatie Avebe U.A. Condiment
JP5672588B2 (en) * 2009-05-26 2015-02-18 株式会社東洋新薬 Diet composition
WO2011068150A1 (en) * 2009-12-04 2011-06-09 株式会社東洋新薬 Glucagon-like peptide-1 secretion enhancer
CN111493254A (en) * 2020-04-10 2020-08-07 苏州绿叶日用品有限公司 A solid beverage containing rhizoma Solani Tuber osi extract and its preparation method

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491578A (en) * 1982-06-14 1985-01-01 Peikin Steven R Method of stimulating satiety in mammals
US4833128A (en) * 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
EP0648495A2 (en) * 1993-07-16 1995-04-19 Hercules Incorporated Cation-complexed polysaccharides
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5595772A (en) * 1995-06-07 1997-01-21 Massachusetts Institute Of Technology Composition and methods for losing weight
US5674896A (en) * 1990-01-22 1997-10-07 Fuji Oil Company, Limited Appetite suppressing agent and use thereof
EP0898900A2 (en) * 1997-06-23 1999-03-03 Societe Des Produits Nestle S.A. Composition and method for providing nutrition to diabetics
WO1999056563A2 (en) * 1998-05-07 1999-11-11 Abbott Laboratories NUTRITIONALLY COMPLETE LOW pH ENTERAL FORMULA
US5989584A (en) * 1994-08-05 1999-11-23 Wisconsin Alumni Research Foundation CCK antibodies used to improve feed efficiency
US6025363A (en) * 1998-11-17 2000-02-15 Giles, Jr.; James A. Composition for suppressing appetite
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US5340603A (en) * 1993-08-30 1994-08-23 Abbott Laboratories Nutritional product for human infants having chronic lung disease

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491578A (en) * 1982-06-14 1985-01-01 Peikin Steven R Method of stimulating satiety in mammals
US4833128A (en) * 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
US5674896A (en) * 1990-01-22 1997-10-07 Fuji Oil Company, Limited Appetite suppressing agent and use thereof
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
EP0648495A2 (en) * 1993-07-16 1995-04-19 Hercules Incorporated Cation-complexed polysaccharides
US5989584A (en) * 1994-08-05 1999-11-23 Wisconsin Alumni Research Foundation CCK antibodies used to improve feed efficiency
US5595772A (en) * 1995-06-07 1997-01-21 Massachusetts Institute Of Technology Composition and methods for losing weight
EP0898900A2 (en) * 1997-06-23 1999-03-03 Societe Des Produits Nestle S.A. Composition and method for providing nutrition to diabetics
WO1999056563A2 (en) * 1998-05-07 1999-11-11 Abbott Laboratories NUTRITIONALLY COMPLETE LOW pH ENTERAL FORMULA
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6025363A (en) * 1998-11-17 2000-02-15 Giles, Jr.; James A. Composition for suppressing appetite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0117541A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334875A (en) * 2017-08-30 2017-11-10 南宁学院 A kind of medicinal liquor for treating diarrhoea and preparation method thereof

Also Published As

Publication number Publication date
JP2003508490A (en) 2003-03-04
EP1115409A1 (en) 2001-07-18
AU779377C (en) 2005-06-30
AU6370400A (en) 2001-04-10
AU779377B2 (en) 2005-01-20
BR0006959A (en) 2001-06-26
JP2005336208A (en) 2005-12-08
MXPA01003054A (en) 2003-07-14
KR20010075394A (en) 2001-08-09
CA2348067A1 (en) 2001-03-15
WO2001017541A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
US20020119915A1 (en) Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety
CN101061860B (en) Leucine-rich nutritional compositions
AU2003287974B2 (en) Blood glucose regulating composition
JP2005336208A (en) Composition for extending post meal satiety
US20100190708A1 (en) Composition for amelioration of body lipid
CN101212961A (en) HMB compositions and uses thereof
TW200812503A (en) Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
ZA200400783B (en) Composition for lowering blood cholesterol
EP1699447B1 (en) Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite
JP2010195779A (en) Hydrolysate of crocin
JP2011514323A (en) Systems and methods using therapeutic nutrition for the management of age-related and age-specific health status of the elderly
GB2323531A (en) Serenoa Repens
KR20150101458A (en) Synergistic dietary supplement for enhancing physical performance
EP1358878A1 (en) Remedies/preventives for inflammatory diseases
CN108135955A (en) muscle-building agent
Gedye Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease
US20040077530A1 (en) Composition for reducing caloric intake
WO1999061028A1 (en) Isoflavonoids for treatment and prevention of migraine headaches
US20060135444A1 (en) Combination of flavonoid and procyanidin for the reduction of the mammalian appetite
WO2001067890A2 (en) Composition and method to treat weight gain and obesity attributable to psychotropic drugs
Horowitz et al. Fenfluramine delays gastric emptying of solid food.
WO2019168149A1 (en) Peptide capable of improving cognitive function
JP4085021B2 (en) Nerve growth factor production inducer
KR20210056283A (en) A composition for preventing or treating insomnia, and preparation method of the same
Ohki et al. The Japanese nutritional health beverage market

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KEMIN CONSUMER CARE, L.C.

A4 Supplementary search report drawn up and despatched

Effective date: 20050301

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 35/78 A

Ipc: 7A 23L 1/29 B

Ipc: 7A 01N 37/18 B

Ipc: 7A 61K 31/78 B

Ipc: 7A 23C 9/152 B

Ipc: 7A 61K 38/01 B

Ipc: 7A 61K 33/06 B

Ipc: 7A 61K 31/20 B

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 33/06 20060101AFI20061110BHEP

Ipc: A61K 38/00 20060101ALI20061110BHEP

Ipc: A61K 38/01 20060101ALI20061110BHEP

Ipc: A61K 31/20 20060101ALI20061110BHEP

Ipc: A61K 36/81 20060101ALI20061110BHEP

Ipc: A01N 37/18 20060101ALI20061110BHEP

Ipc: A61K 31/78 20060101ALI20061110BHEP

Ipc: A23L 1/29 20060101ALI20061110BHEP

Ipc: A23C 9/152 20060101ALI20061110BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061114